Skip to main content

Teleflex Value Stock - Dividend - Research Selection

Teleflex

ISIN: US8793691069 , WKN: 855853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Teleflex Incorporated (TFX) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18
Teleflex Incorporated (TFX) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM ESTCompany ParticipantsLiam Kelly - Chairman, President...

Don't Overlook Teleflex (TFX) International Revenue Trends While Assessing the Stock

2025-11-17
Explore Teleflex's (TFX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Teleflex Incorporated (TFX) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business - Slideshow

2025-11-16
2025-11-16. The following slide deck was published by Teleflex Incorporated in conjunction with this event.

Teleflex (TFX): Evaluating Valuation Prospects Following Share Price Decline

2025-11-15
Teleflex (TFX) shares have been on a downward trend, slipping 12% over the past month and 40% lower year to date. Investors are watching closely because these moves raise questions about the company’s current valuation and future direction. See our latest analysis for Teleflex. This sharp drop in Teleflex’s share price puts it firmly on investors’ radar, especially since its 1-year total shareholder return of -43.7% highlights just how much momentum has faded compared to earlier years. Recent...

Teleflex Incorporated (TFX) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business Transcript

2025-11-14
Teleflex Incorporated (TFX) Discusses Strategic Rationale and Portfolio Overview of Acquired Vascular Intervention Business November 14, 2025 8:00 AM...

Teleflex to Present at the Jefferies Global Healthcare Conference in London

2025-11-14
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. (GMT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality

3 Value Stocks That Concern Us

2025-11-14
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

TFX Stock Falls Despite Q3 Earnings and Revenue Beat, '25 View Down

2025-11-13
Teleflex posts strong Q3 earnings and revenue beats but trims 2025 outlook, sending shares slightly lower.

3 Reasons to Sell TFX and 1 Stock to Buy Instead

2025-11-13
Over the last six months, Teleflex’s shares have sunk to $111.34, producing a disappointing 12.2% loss - a stark contrast to the S&P 500’s 16.4% gain. This may have investors wondering how to approach the situation.

3 Unprofitable Stocks That Concern Us

2025-11-12
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.